Quantcast

Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030 Markets – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Novel
Technologies for Delivery of Proteins, Antibodies and Nucleic Acids,
2019-2030”
report has been added to ResearchAndMarkets.com’s
offering.

The Novel Technologies for Delivery of Proteins, Antibodies, and Nucleic
Acids, 2019-2030 report features an extensive study of the current
market landscape and the likely future adoption of such technologies,
over the next twelve years.

One of the key objectives of the report was to estimate the existing
market size and identify potential future growth opportunities for novel
technologies designed for the administration of proteins, antibodies,
and nucleic acids. Based on likely licensing deal structures and
agreements that are expected to be signed in the foreseen future, we
have provided an informed estimate on the evolution of the market over
the period 2018-2030.

The report features likely distribution of the current and forecasted
opportunity across the [A] type of therapeutic area (oncology and
non-oncology), [B] route of administration (parenteral and
non-parenteral), [C] key contributing technologies and [D] key
geographical regions (North America, Europe, Asia Pacific and rest of
the world). In order to account for future uncertainties and to add
robustness to our model, we have provided three market forecast
scenarios, namely conservative, base and optimistic scenarios,
representing different tracks of the industry’s growth.

The study features in-depth analysis, highlighting:

  • A detailed assessment of the current market landscape of companies
    offering technologies for delivery of biotherapeutics, including
    information on their geographical location, types of biologics
    delivered (proteins, peptides, antibodies and nucleic acids), routes
    of administration used (parenteral, oral, transdermal / topical,
    inhalation and others) and impact on drug properties / patient
    compliance.
  • A comprehensive competitiveness analysis of the drug delivery
    technologies captured in our report database, taking into
    consideration the supplier power (based on year of establishment) and
    key technology-related specifications, such as the type(s) of
    biologics delivered, the extent of the impact on drug properties,
    patient compliance and the route of administration.
  • Elaborate profiles of prominent technology developers engaged in this
    domain, featuring a brief overview of the company, its financial
    performance (if available), information on its product portfolio,
    recent developments and a comprehensive future outlook. Additionally,
    the report includes profiles of certain technologies that emerged as
    relatively superior in our proprietary competitiveness analysis.
  • An in-depth analysis of the various patents that have been filed and
    granted related to novel drug delivery technologies, till November
    2018. It includes information on key parameters, such as patent type,
    publication year, issuing authority, CPC classification, emerging
    focus areas and leading industry / academic players (in terms of the
    size of the intellectual property portfolio).
  • A detailed analysis of the partnerships and collaborations focused on
    technologies for the delivery of biotherapeutics, featuring a
    comprehensive set of analyses based on various parameters, such as the
    year of establishment, type of partnership, type of therapeutic areas,
    most active players and geographical location.
  • A discussion on the upcoming opportunities in the field of
    biotherapeutic drug delivery that are likely to impact the evolution
    of this market in the coming years.

Key Topics Covered:

1. Preface

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. Executive Summary

3. Introduction

3.1. An Overview of Biopharmaceuticals

3.2. Demand for Biopharmaceuticals

3.3. Types of Biopharmaceuticals

3.3.1. Proteins and Peptides

3.3.2. Antibodies

3.3.3. Nucleic Acids

3.4. Common Routes of Administration for Biopharmaceuticals

3.4.1. Parenteral Delivery

3.4.1.1. Intravenous Route

3.4.1.2. Intramuscular Route

3.4.1.3. Subcutaneous Route

3.4.2. Non-Parenteral Delivery

3.4.2.1. Buccal / Sublingual Route

3.4.2.2. Intranasal Route

3.4.2.3. Inhalation / Pulmonary Route

3.4.2.4. Ocular Route

3.4.2.5. Oral Route

3.4.2.6. Rectal Route

3.4.2.7. Transdermal Route

3.5. Key Challenges Associated with Drug Delivery

3.6. Advanced Approaches for Delivery of Biotherapeutics

3.6.1. Muco-Adhesive Polymeric Systems

3.6.2. Nanoparticle-based Delivery Systems

3.6.3. Other Drug Delivery Technologies

3.7. Demand for Novel Drug Delivery Technologies

3.8. Concluding Remarks

4. Market Landscape

4.1. Chapter Overview

4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids:
Overall Market Landscape

4.2.1. Analysis by Size of Developer Company

4.2.2. Analysis by Year of Establishment

4.2.3. Analysis by Type of Technology

4.2.4. Analysis by Type of Biologics Delivered

4.2.5. Analysis by Impact of Technology on Drug Properties / Patient
Compliance

4.2.6. Analysis by Route of Administration

4.2.7. Analysis by Geographical Location of Developer Company

4.3. Grid Analysis: Distribution by Type of Biologics, Route of
Administration and Drug Delivery Parameters

4.4. List of Drug Formulation Technologies

5. Product Competitiveness Analysis

5.1. Chapter Overview

5.2. Product Competitiveness Analysis: Key Assumptions and Methodology

5.2.1. Technologies of Companies Based in North America

5.2.2. Technologies of Companies Based in Europe

5.2.3. Technologies of Companies Based in Asia-Pacific

6. Technology Profiles

6.1. Chapter Overview

6.2. Intravail Technology

6.3. RapidMist

6.4. TheraKine Technology

6.5. Arestat Technology

6.6. DelSiTech Silica Matrix

6.7. ImSus Technology

6.8. PLEX Technology

6.9. ENHANZE Technology

7. Company Profiles: Drug Delivery Platform Providers

7.1. Chapter Overview

7.2. Aphios

7.3. Arbutus Biopharma

7.4. Camurus

7.5. ConjuChem

7.6. InnoCore Pharmaceuticals

7.7. LATITUDE Pharmaceuticals

8. Patent Analysis

8.1. Chapter Overview

8.2. Scope and Methodology

8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic
Acids: Patent Analysis

8.3.1. Analysis by Publication Year

8.3.2. Analysis by Issuing Authority / Patent Offices Involved

8.3.3. Analysis by CPC Classification

8.3.4. Emerging Focus Areas

8.3.5. Leading Players Based on Number of Patents

8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic
Acids: Patent Benchmarking Analysis

8.4.1. Analysis by Patent Characteristics

8.4.2. Analysis by Geography

8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids:
Patent Valuation Analysis

9. Recent Partnerships

9.1. Chapter Overview

9.2. Partnership Models

9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List
of Partnerships and Collaborations

10. Market Sizing And Opportunity Analysis

10.1. Chapter Overview

10.2. Forecast Methodology and Key Assumptions

10.3. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Information on Licensing Deals

10.4. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Overall Market, 2019-2030

10.5. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Region, 2019 and 2030

10.6. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030

10.7. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas

10.8. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030

10.9. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030

11. Future Growth Opportunities

11.1. Chapter Overview

11.2. The Industry Has Recently Witnessed A Shift from Conventional
Nanoparticle-Based Technologies to DNA-Based Solutions

11.3. Despite Extensive Research Efforts in this Domain, There is Still
A Substantial Unmet Need Related To Drug Delivery Technologies For
Neurodegenerative Disorders

11.4. The Oral Route of Delivery, Owing to its Capability to Ensure
Therapy Adherence, Has Garnered Significant Attention in this Market

11.5. Impending Patent Expirations Have Prompted Many Players to Adopt
Various Life Cycle Management Strategies to Sustain Revenue Generation
Potential

11.6. The Larger Market Share is Currently with the Developed Regions,
while Contributions from Technology Providers in the Asia Pacific are
Expected to Increase in the Foreseen Future

12. Executive Insights

12.1. Chapter Overview

12.2. ArmaGen

12.2.1. Company Snapshot

12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer

12.3. ICB International

12.3.1. Company Snapshot

12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer,
Chairman and Founder

12.4. KAER Biotherapeutics

12.4.1. Company Snapshot

12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer
and Chief Scientific Officer, Chairman and Founder

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies And Organizations

  • 4P Therapeutics
  • Abbott Laboratories
  • AbbVie
  • Acuitas Therapeutics
  • ADAMA
  • Adhera Therapeutics
  • Adimab
  • ADOCIA
  • Aegis Therapeutics
  • Aerogen
  • AIMM Therapeutics
  • Ajinomoto Bio-Pharma Services
  • Albireo Pharma
  • Alchemia
  • Alexion Pharmaceuticals
  • Allergan
  • ALRISE Biosystems
  • Alteogen
  • AMAG Pharmaceuticals
  • Amarantus BioScience Holdings
  • Amgen
  • Antares Pharma
  • Antibody Solutions
  • Aphios
  • Applied Molecular Transport
  • Apricus Biosciences
  • Aquarius Biotechnologies
  • Aquestive Therapeutics
  • Aradigm
  • Arbutus Biopharma
  • Arecor
  • ArmaGen
  • Ascendis Pharma
  • Astellas Research Institute of America
  • AstraZeneca
  • Avadel Pharmaceuticals
  • Bausch Health Companies
  • Baxter International
  • Bayer
  • BBI Solutions
  • BGN Technologies
  • Bio-Path Holdings
  • Bioasis Technologies
  • BioCardia
  • BioCorRx
  • Biogen
  • BiondVax Pharmaceuticals
  • Biovail Laboratories
  • Boehringer Ingelheim
  • Brigham and Women’s Hospital
  • Bristol-Myers Squibb
  • C-TRI
  • Caisson Biotech
  • Camurus
  • CannScience Innovations
  • Capsugel
  • Catalent Pharma Solutions
  • Cell Care Therapeutics
  • Centre for Process Innovation
  • Cerenis Therapeutics
  • Chembio Diagnostics
  • Chugai Pharmaceutical
  • ConjuChem Biotechnologies
  • CordenPharma
  • Corium International
  • CSL Behring
  • Cureport
  • Dauntless Pharmaceuticals
  • Delpor
  • DelSiTech
  • Dendreon
  • Diabetology
  • Dicerna Pharmaceuticals
  • Dr Reddy’s Laboratories
  • Eisai
  • Elasmogen
  • Eli Lilly and Company
  • Elusys Therapeutics
  • Emergent BioSolutions
  • Emergent Technology
  • Emisphere Technologies
  • enGene
  • Engineered BioPharmaceuticals
  • Epeius Biotechnologies
  • EuMederis Pharmaceuticals
  • Evonik
  • Excelse Bio
  • Exicure
  • Feldan Therapeutics
  • Ferring Pharmaceuticals
  • Flex
  • Foresee Pharmaceuticals
  • FUJIFILM Diosynth Biotechnologies
  • Genentech
  • Generex Biotechnology
  • Genexine
  • Genisphere
  • Genmab
  • GlaxoSmithKline
  • Graybug Vision
  • Green Cross Labcell
  • Gritstone Oncology
  • Halozyme Therapeutics
  • Heron Therapeutics
  • Hovione
  • Human Stem Cells Institute
  • ICB International
  • Ichor Medical Systems
  • ImClone Systems
  • Indivior UK
  • InnoCore Pharmaceuticals
  • Inovio Pharmaceuticals
  • Inserm
  • InteRNA Technologies
  • Invenra
  • Ionis Pharmaceuticals
  • Janssen Pharmaceuticals
  • Jerini
  • Johnson & Johnson
  • KAER Biotherapeutics
  • Kolon Life Science
  • Kolon TissueGene
  • Kurve Technology
  • Kyowa Hakko Kirin
  • Lankenau Institute for Medical Research (LIMR)
  • LATITUDE Pharmaceuticals
  • Lauren Sciences
  • Longevity Biotech
  • Lupin Pharmaceuticals
  • Lyndra Therapeutics
  • MannKind
  • Matinas BioPharma
  • Medesis Pharma
  • MedImmune
  • Merck
  • Merrion Pharmaceuticals
  • Merz Pharma
  • MiNA Therapeutics
  • Mitsubishi Tanabe Pharma
  • MonoSol
  • Monsanto
  • Mountain View Pharmaceuticals
  • MultiCell Technologies
  • Mylan
  • Nanexa
  • NanoCarrier
  • Nanomi
  • National Institute of Neurological Disorders and Stroke
  • NBE-Therapeutics
  • Neurelis
  • NHTherapeutics
  • NOD Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Novosom
  • Nutriband
  • Oakwood Labs
  • Octapharma
  • Ocular Therapeutix
  • Oncotelic
  • Opiant Pharmaceuticals
  • OPKO Biologics
  • Oramed Pharmaceuticals
  • Orbis Biosciences
  • Pacira Pharmaceuticals
  • Peptineo
  • Peptron
  • PepVax
  • Pfizer
  • PharmaIN
  • PhaseBio Pharmaceuticals
  • Phylogica
  • Pickwick Capital Partners
  • PolyPid
  • Precision NanoSystems
  • Profectus BioSciences
  • Prometheon Pharma
  • Prometheus Laboratories
  • Prothena
  • Proxima Concepts
  • Pulmatrix
  • Purdue Pharma
  • Rani Therapeutics
  • Receptor Life Sciences
  • Regeneron Pharmaceuticals
  • Rett Syndrome Research Trust
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Roche
  • Roivant Sciences
  • RoverMed BioSciences
  • San Diego Hospice and The Institute for Palliative Medicine
  • Sanofi
  • Savient Pharmaceuticals
  • ScinoPharm
  • Scripps Research
  • Serina Therapeutics
  • Seton Healthcare Family
  • Shanghai Sunway Biotech
  • Sibiono GeneTech
  • Sierra Oncology
  • SmooFi
  • Solani Therapeutics
  • Spark Therapeutics
  • Strides Pharma Science
  • SUDA Pharmaceuticals
  • Swedish Orphan Biovitrum
  • Synthelis
  • Takeda Oncology
  • Takeda Pharmaceutical
  • Tamarisk Technologies Group
  • Tarix Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Teva Respiratory
  • The Jordanian Pharmaceutical Manufacturing
  • Theraclone Sciences
  • TheraKine
  • Thomas Jefferson University
  • Transdermal
  • UCB
  • University of Maryland
  • University of North Texas Health Science Center
  • University of Pennsylvania
  • Valerion Therapeutics
  • Velocity Pharmaceutical Development
  • Vical
  • ViroPharma
  • ViroVet
  • Xenetic Biosciences
  • XL-protein

For more information about this report visit https://www.researchandmarkets.com/r/kkur78

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.